The therapeutic monitoring protocol adopts a two-phase approach: during the initial treatment phase, CBC, inflammatory markers (IL-6, C-reactive protein), and symptom scores (MPN-10 scale) are monitored every 4-8 weeks; in the long-term management phase, CBC, splenomegaly index, and bone marrow biopsy are reviewed every three months, with cardiovascular risk reassessment updated every six months [11,13]. Here, IL6 is linked to Splenomegaly.